Non small cell lung cancer
Conditions
Interventions
Bevacizumab injection group:None
Immune checkpoint inhibitors+Platinum based double drug chemotherapy group:None
Bevacizumab injection+Platinum based double drug chemotherapy group:None
Bevacizumab injection+Immune checkpoint inhibitors+Platinum based double drug chemotherapy group:None
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.The patients were diagnosed as malignant tumor by histology or cytology; 2.During this hospitalization, he received bevacizumab injection. Economic evaluation: 1.Pathological diagnosis was non-small cell lung cancer (NSCLC); 2.Aged >= 18 years; 3.There is no driving gene or the driving gene is unknown; 4.According to AJCC 8th edition staging criteria, patients with locally advanced, metastatic or recurrent (stage III B ~ IV) non squamous non-small cell lung cancer were clinically diagnosed as unresectable; 5.Measurable lesions defined by at least one solid tumor response assessment standard (RECIST version 1.1); 6.ECoG score was 0-2; 7.Life expectancy >= 6 months; 8.Patients were informed and voluntarily participated in the study.
Exclusion criteria
Exclusion criteria: 1.The subjects' compliance was poor, which affected the safety evaluation; 2.Those with special physiological changes should not continue to accept the test; 3.If the information is incomplete and affects the safety judgment, it will not be included in the final data analysis. Economic evaluation: 1.Patients with other tumors; 2.Patients with severe central nervous system disease, heart disease and severe liver and kidney function damage; 3.Received neoadjuvant chemotherapy or adjuvant chemotherapy and less than 6 months from the time of enrollment; 4.Patients with recent active bleeding or recent hemoptysis (>= 1 / 2 teaspoon of blood); 5.Uncontrolled hypertension and hypertensive crisis patients; 6.Patients who planned to undergo major traumatic surgery within 4 weeks before administration or during the study period, or whose wounds were not fully healed within 4 weeks before administration; 7.Patients with previous gastrointestinal perforation or fistula, or with previous use of bevacizumab injection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival;Progress-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Disease control rate; | — |
Countries
China
Contacts
Public ContactShi Chen
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed